Clinical and Experimental Respiratory Immunoallergy, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Centre de Recerca Biomèdica CELLEX, Casanova 143, 08036, Barcelona, Catalonia, Spain,
Curr Allergy Asthma Rep. 2015 May;15(5):19. doi: 10.1007/s11882-015-0520-6.
Chronic rhinosinusitis (CRS) is a chronic inflammatory disease of the upper airways of which two major phenotypes exist, CRS without nasal polyps (CRSsNP) and CRS with nasal polyps (CRSwNP). Some patients with CRS have suboptimal response to current guideline treatments. These patients remain severe and uncontrolled by treatment and have a poor quality of life. It is highly important to identify both clinical and biological markers, so-called biomarkers, in this subset of patients. The presence of nasal polyps and comorbidity with asthma and with aspirin-exacerbated respiratory disease (AERD) are the most common clinical traits that have been associated to difficult-to-treat severe CRS. In addition to clinical traits, numerous biological markers, with known etiopathogenic roles in CRS, have been associated to difficult-to-treat or recalcitrant CRS. This review summarizes the existing knowledge of the clinical and biological markers associated to difficult-to-treat or uncontrolled severe CRS.
慢性鼻-鼻窦炎(CRS)是一种上呼吸道的慢性炎症性疾病,存在两种主要表型,即无鼻息肉的 CRS(CRSsNP)和有鼻息肉的 CRS(CRSwNP)。一些 CRS 患者对当前指南治疗的反应不佳。这些患者的治疗效果仍然不佳且无法控制,生活质量较差。在这部分患者中,识别临床和生物标志物(所谓的生物标志物)非常重要。存在鼻息肉以及与哮喘和阿司匹林加重性呼吸道疾病(AERD)的合并症是与难以治疗的严重 CRS 最相关的最常见临床特征。除了临床特征外,许多具有已知在 CRS 中发病机制作用的生物标志物也与难以治疗或难治性 CRS 相关。这篇综述总结了与难以治疗或不受控制的严重 CRS 相关的临床和生物标志物的现有知识。
Curr Allergy Asthma Rep. 2015-5
Laryngorhinootologie. 2013-3
Int Forum Allergy Rhinol. 2020-2
Int Forum Allergy Rhinol. 2014-1-2
J Allergy Clin Immunol Pract. 2016
J Allergy Clin Immunol Pract. 2017-3-9
Ann Allergy Asthma Immunol. 2020-3-30
Eur Arch Otorhinolaryngol. 2016-8
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016-7-20
J Allergy Clin Immunol. 2015-12
Int J Immunopathol Pharmacol. 2020
Braz J Otorhinolaryngol. 2021
Immune Netw. 2019-2-4
J Thorac Dis. 2018-12
Curr Allergy Asthma Rep. 2017-4
Curr Allergy Asthma Rep. 2017-2
Clin Exp Allergy. 2015-2
Clin Exp Allergy. 2015-2
J Allergy Clin Immunol. 2014-8-23
Ann Allergy Asthma Immunol. 2014-7-16
Int Arch Allergy Immunol. 2014
J Allergy Clin Immunol. 2014-5